About Cytochroma
Inc.:
Cytochroma Inc. is a clinical
stage specialty pharmaceutical company that designs, develops
and commercializes prescription products to treat and prevent
the clinical consequences of vitamin D insufficiency and secondary
hyperparathyroidism (SHPT) associated
with chronic kidney disease (CKD). The Company has an advanced
portfolio of new therapies designed to safely and effectively
treat patients with vitamin D insufficiency and SHPT associated
with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing
novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia)
in order to improve the control of SHPT in CKD patients.
Cytochroma
has three lead product candidates in development for CKD patients—CTA018
Injection
and CTAP201 Injection for the treatment of SHPT and CTAP101 Capsules
for the treatment of vitamin D insufficiency. The
Company’s lead products address a significant need for
new therapeutic options to better control these disorders and
their associated morbidities such as endocrine, cardiovascular,
and bone and mineral diseases. Cytochroma’s vitamin-D
based therapeutics address target markets projected to reach
more than $1.4 billion annually by 2013 in the U.S.
Cytochroma’s
expertise in vitamin D chemistry, biochemistry, metabolism and
physiology, combined with its experience in bringing vitamin
D-based therapeutics to market uniquely positions the Company
to improve the lives of CKD patients suffering from diseases
related to vitamin D insufficiency and SHPT. |